Clinical outcomes in patients with systemic lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of results from the OBSErve study in Switzerland by von Kempis, Johannes et al.
Zurich Open Repository and
Archive
University of Zurich
Main Library
Strickhofstrasse 39
CH-8057 Zurich
www.zora.uzh.ch
Year: 2019
Clinical outcomes in patients with systemic lupus erythematosus treated
with belimumab in clinical practice settings: a retrospective analysis of
results from the OBSErve study in Switzerland
von Kempis, Johannes; Duetsch, Sabine; Reuschling, Nicola; Villiger, Rahel; Villiger, Peter M;
Vallelian, Florence; Schaer, Dominik J; Mueller, Ruediger B
Abstract: AIMS OF THE STUDY To describe patterns of systemic lupus erythematosus (SLE) care
and the clinical effectiveness of belimumab plus standard of care therapy in a real-world clinical setting
in Switzerland. METHODS This multicentre, observational, retrospective cohort study included adults
with SLE who initiated belimumab as part of their usual care at least six months before data analysis.
The primary outcome was the overall clinical response, assessed by a physician on a Physician’s Global
Assessment-like scale, to six months’ treatment with belimumab. Secondary outcomes included improve-
ment in disease activity, SLE manifestations and changes in corticosteroid use. RESULTS 53 patients
(81% female) from three hospitals were included. At index (belimumab initiation), 23 patients (43%)
had mild, 23 (43%) had moderate, and 7 (13%) had severe SLE. Overall improvement in disease activity
in patients receiving belimumab was: ￿80% in 6 patients (11%), ￿50% in 12 (23%), ￿20% in 31 (58%),
<20% in 13 (25%), and no improvement in 9 (17%). Mean Safety of Estrogens in Lupus Erythematosus
National Assessment-SLE Disease Activity Index score decreased from 8.0 at index to 3.6 at six months
post index in the 27 patients assessed. In addition, a ￿50% improvement in arthritis, fatigue, rash, low
complement (C3, C4 or total haemolytic complement activity), and anti-double-stranded deoxyribonu-
cleic acid antibody levels was experienced six months post index by 10 (38%), 3 (16%), 6 (38%), 2 (12%)
and 4 (16%) patients who presented the manifestations at index respectively. At index, 41 patients (77%)
received oral corticosteroids at a mean dose of 11.6 mg/day, which decreased to 5.9 mg/day at six months
post index. Of the 31 patients receiving a high dose of corticosteroids (￿7.5 mg/day) at index, 18 required
<7.5 mg/day and a further two discontinued corticosteroids at six months post index. CONCLUSIONS
This study provides real-world insight into belimumab use in clinical practice in Switzerland. In line with
findings from other countries, Swiss patients with SLE who received belimumab demonstrated clinical
and serological improvements in SLE and a reduction in corticosteroid use after six months of treatment.
DOI: https://doi.org/10.4414/smw.2019.20022
Posted at the Zurich Open Repository and Archive, University of Zurich
ZORA URL: https://doi.org/10.5167/uzh-170458
Journal Article
Published Version
 
 
The following work is licensed under a Creative Commons: Attribution-NonCommercial-NoDerivatives
4.0 International (CC BY-NC-ND 4.0) License.
Originally published at:
von Kempis, Johannes; Duetsch, Sabine; Reuschling, Nicola; Villiger, Rahel; Villiger, Peter M; Vallelian,
Florence; Schaer, Dominik J; Mueller, Ruediger B (2019). Clinical outcomes in patients with systemic
lupus erythematosus treated with belimumab in clinical practice settings: a retrospective analysis of
results from the OBSErve study in Switzerland. Swiss Medical Weekly, 149:w20022.
DOI: https://doi.org/10.4414/smw.2019.20022
2
Original article | Published 10 March 2019 | doi:10.4414/smw.2019.20022
Cite this as: Swiss Med Wkly. 2019;149:w20022
Clinical outcomes in patients with systemic lupus
erythematosus treated with belimumab in clinical
practice settings: a retrospective analysis of
results from the OBSErve study in Switzerland
von Kempis Johannesa, Duetsch Sabineb, Reuschling Nicolac, Villiger Raheld, Villiger Peter Md, Vallelian Florencee, Schaer
Dominik Je, Mueller Ruediger Baf
a Division of Rheumatology and Immunology, Department of Internal Medicine, Kantonsspital St. Gallen, St. Gallen, Switzerland
b GlaxoSmithKline AG, Münchenbuchsee, Switzerland
c Klinik Birshof, Münchenstein, Switzerland
d Department of Rheumatology, Immunology and Allergology, University Hospital and University of Bern, Bern, Switzerland
e Division of Internal Medicine, University Hospital of Zurich, Zurich, Switzerland
f Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig Maximilian University of Munich, Munich, Germany
Summary
AIMS OF THE STUDY: To describe patterns of systemic
lupus erythematosus (SLE) care and the clinical effective-
ness of belimumab plus standard of care therapy in a real-
world clinical setting in Switzerland.
METHODS: This multicentre, observational, retrospective
cohort study included adults with SLE who initiated beli-
mumab as part of their usual care at least six months be-
fore data analysis. The primary outcome was the overall
clinical response, assessed by a physician on a Physi-
cian’s Global Assessment-like scale, to six months’ treat-
ment with belimumab. Secondary outcomes included im-
provement in disease activity, SLE manifestations and
changes in corticosteroid use.
RESULTS: 53 patients (81% female) from three hospitals
were included. At index (belimumab initiation), 23 patients
(43%) had mild, 23 (43%) had moderate, and 7 (13%) had
severe SLE. Overall improvement in disease activity in pa-
tients receiving belimumab was: ≥80% in 6 patients (11%),
≥50% in 12 (23%), ≥20% in 31 (58%), <20% in 13 (25%),
and no improvement in 9 (17%). Mean Safety of Estrogens
in Lupus Erythematosus National Assessment-SLE Dis-
ease Activity Index score decreased from 8.0 at index to
3.6 at six months post index in the 27 patients assessed.
In addition, a ≥50% improvement in arthritis, fatigue, rash,
low complement (C3, C4 or total haemolytic complement
activity), and anti-double-stranded deoxyribonucleic acid
antibody levels was experienced six months post index by
10 (38%), 3 (16%), 6 (38%), 2 (12%) and 4 (16%) patients
who presented the manifestations at index respectively. At
index, 41 patients (77%) received oral corticosteroids at a
mean dose of 11.6 mg/day, which decreased to 5.9 mg/
day at six months post index. Of the 31 patients receiving
a high dose of corticosteroids (≥7.5 mg/day) at index, 18
required <7.5 mg/day and a further two discontinued corti-
costeroids at six months post index.
CONCLUSIONS: This study provides real-world insight in-
to belimumab use in clinical practice in Switzerland. In line
with findings from other countries, Swiss patients with SLE
who received belimumab demonstrated clinical and sero-
logical improvements in SLE and a reduction in corticos-
teroid use after six months of treatment.
Keywords: belimumab, B-cell-targeted therapy, systemic
lupus erythematosus, SLE, real-world, effectiveness,
steroid sparing, disease activity, observational study
Introduction
Systemic lupus erythematosus (SLE) is a chronic autoim-
mune disease with a heterogeneous presentation. SLE af-
fects a variety of organ systems, including the skin, heart,
joints, kidneys and central nervous system [1]. The es-
timated incidence of SLE in western European countries
ranges from 2.2 to 5.0/100,000, with a prevalence of
25.4–91/100,000 [2]. The majority of patients with SLE re-
quire lifelong medication to manage disease activity. Such
medications include oral corticosteroids, antimalarials,
non-steroidal anti-inflammatory drugs (NSAIDs), cytotox-
ic agents and conventional synthetic and biological dis-
ease-modifying anti-rheumatic drugs [3]. Prolonged treat-
ment with these therapies, especially high-dose
corticosteroids and immunomodulatory therapies, is asso-
ciated with significant morbidity [4, 5].
SLE is characterised by elevated circulating levels of B
lymphocyte stimulator (BLyS), also known as B cell-ac-
tivating factor (BAFF), a member of the tumour necrosis
factor ligand superfamily that promotes abnormal B cell
activation and differentiation [6, 7]. Belimumab is a re-
combinant immunoglobulin G1λ monoclonal antibody that
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binds soluble BLyS and neutralises its biological activity
[8]. In Switzerland, belimumab is indicated as add-on ther-
apy in adult patients with active, autoantibody-positive
SLE [9], and is reimbursed for patients with a high degree
of serological activity (e.g., positive anti-double-stranded
deoxyribonucleic acid (dsDNA) antibodies and low com-
plement levels). While the efficacy and safety of intra-
venous (IV) belimumab plus standard of care (SoC) ther-
apy in patients with active SLE has been demonstrated
in three large Phase III trials [10–12], data on its clinical
benefit in everyday clinical practice are scarce. OBSErve
(evaluation Of use of Belimumab in clinical practice SEt-
tings) is a multinational study programme comprising ob-
servational studies designed to assess treatment utilisation
and clinical outcomes of belimumab therapy in real-world
settings. The OBSErve studies were conducted to provide
a more realistic reflection of the overall patterns of SLE
care compared with clinical trials. The first OBSErve study
was conducted in the United States. Additional studies
have now been completed in Germany, Canada, Spain and
Argentina [13–17]. In these real-world practice settings,
patients with SLE showed overall clinical improvements in
SLE and a reduction in corticosteroid use and healthcare
resource utilisation.
This study aims to investigate treatment patterns in patients
with SLE and the clinical effectiveness of six months of
belimumab therapy in patients who received belimumab
plus SoC therapy as part of their usual care in clinical prac-
tice in Switzerland.
Materials and methods
Study design
This was a multicentre, observational cohort study (GSK
study number 201232) designed to retrospectively analyse
real-world information on the short-term outcomes of be-
limumab use in patients with SLE from patient medical
records. As the study was retrospective, the protocol had
no influence on treatment decisions or the collection of
patient data. Data were collected at three time points: six
months prior to belimumab initiation, at belimumab ini-
tiation (index date, between September 2012 and March
2016), and six months after index (or at time of discon-
tinuation). The study period included a treatment history
period (pre index) of six months and a post index follow-
up of six months. This allowed for an observation period
of approximately 12 months for patients who did not dis-
continue treatment. The reporting of this study conforms to
the Strengthening the Reporting of Observational Studies
in Epidemiology (STROBE) guidelines [18].
Study sites and physicians
Physicians (rheumatologists or internal medicine physi-
cians) who at the time of recruitment managed/treated at
least 10 patients with SLE, had ≥5 years’ experience in
treating patients with SLE, had ≥6 months’ experience in
belimumab use, had treated at least two patients with beli-
mumab plus SoC and who were currently treating at least
one patient with belimumab plus SoC participated in the
study. Physicians completed a physician practice profile
form (PPPF), which captured information regarding their
medical practices and approaches to the management of
SLE, such as routine use of laboratory tests and disease ac-
tivity assessment tools. Six of the leading academic centres
with specialised SLE clinics in the German-speaking parts
of the country were contacted, and three agreed to partici-
pate in the study. Treating physicians at the three sites (site
1: three physicians; site 2: three physicians; and site 3: two
physicians) received continuous training for the diagnosis
and treatment of patients with SLE during the study peri-
od.
Patient inclusion and exclusion criteria
Physicians enrolled all patients from their practices who
fulfilled the following inclusion criteria: adults aged ≥18
years with a confirmed SLE diagnosis who had initiated
belimumab plus SoC at least six months before inclusion,
for whom reasons for belimumab initiation and discontinu-
ation could be identified, whose medical history was avail-
able for up to six months pre index, and whose treatment
outcomes were available at six months post index or at dis-
continuation. Patients already enrolled in an SLE-related
clinical trial, or who started belimumab as part of a clinical
trial in an intervention arm, were excluded. All patient da-
ta were anonymised. To avoid selection bias, all patients in
whom belimumab was initiated as part of their usual care
six months before documentation, and who met the inclu-
sion criteria (including patients who had discontinued beli-
mumab in the past), were considered for inclusion.
Physicians extracted data from patient medical records on-
to the patient case report form (CRF). CRFs contained pa-
tient information on demographics and clinical character-
istics, SLE disease characteristics at index, treatment and
clinical outcomes.
Ethical considerations
The study was conducted according to the Guidelines for
Good Pharmacoepidemiology Practices and the Guideline
for Good Clinical Practice [19, 20]. The study and all study
documentation were approved by the lead ethics commit-
tee in St. Gallen and subsequently approved by ethics com-
mittees in Zurich and Bern (approval number: EKSG 14/
128/L). Written informed consent was obtained from all
participating patients.
Objectives
The primary objective was to describe the pattern of SLE
care and outcomes among patients receiving belimumab
for six months, in clinical practice in Switzerland. Sec-
ondary objectives were to describe characteristics of the
patients, reasons for initiation and discontinuation of be-
limumab, changes in disease activity as assessed by the
Safety of Estrogens in Lupus Erythematosus National As-
sessment (SELENA) SLE Disease Activity Index
(SLEDAI), and use of concomitant medications for pa-
tients treated with belimumab.
Endpoints
The primary endpoint was the overall clinical response to
six months of belimumab treatment, reported as a percent-
age of patients with specific levels of clinical improve-
ment since the index date, as assessed by the physician
on a Physician’s Global Assessment (PGA)-like scale, and
categorised as worse, no improvement, improvement of
<20%, 20–49%, 50–79%, or ≥80%. The endpoints to as-
sess the pattern of SLE care were the use of different
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disease activity instruments and laboratory measures as
part of regular SLE management. Endpoints to assess pa-
tient outcomes included: clinical response of specific SLE
manifestations/organ specific improvement (based on the
physician’s judgement, analogous to the assessment of the
overall clinical response); change in disease activity (SE-
LENA-SLEDAI score or other disease activity indices,
calculated retrospectively by the physician during data col-
lection); treatment patterns of concomitant medication,
particularly corticosteroids: dose reduction and switching
from high doses (≥7.5 mg/day) to low doses (<7.5 mg/
day); and rate of discontinuation of belimumab. The SE-
LENA-SLEDAI analyses 24 items relating to nine organ
systems, with scores ranging from 0 to 105 [21]. An in-
crease in SELENA-SLEDAI of >3 points has been sug-
gested as indicative of a flare, and a reduction of >3 points
as an improvement [22, 23]. Therefore, a reduction of more
than 3 points was chosen to represent a clinically meaning-
ful difference in disease activity.
Although safety assessment was not an objective of this
study, adverse events (AEs) were reported to the local/na-
tional regulatory authorities or to the study sponsor, as ap-
propriate.
Statistical analyses
Owing to the largely exploratory nature of the study, no
formal sample size calculations were performed to deter-
mine the number of physicians and patients to be includ-
ed in the study. Based on feasibility, the target sample
size was 40 patients. Analyses were conducted on the full
analysis set (FAS), defined as all valid cases (patients who
fulfilled the inclusion criteria, and for whom completed
CRFs were available) from eligible sites (sites that fulfilled
the physician inclusion criteria, and completed the PPPF).
Descriptive statistics were used to analyse the categorical
and quantitative data (IBM SPSS Statistics 22 software
was used). No analyses of loss to follow-up, incomplete
case documentation or deviations from the target study
population were undertaken. No imputation for missing
data was used.
Results
Participating sites and physicians
Three hospital sites participated in the study. The mean
(standard deviation [SD]) physician experience in treat-
ment of patients with SLE was 8.7 (4.62) years (range
6–14 years), and the mean number of patients with SLE
under the care of each physician/site was 60 (range
30–100). Of these, a mean of 21 patients per physician
(range 12–31) had been treated with belimumab plus SoC
at some point, a mean of 19 patients were under active
treatment at the time of data collection, and 11 had been
treated with belimumab for at least six months.
The use of disease assessment tools varied between sites,
with only one site routinely using a PGA scale, a SLEDAI
or SELENA-SLEDAI, or a Fatigue Severity Scale in their
SLE management. In all three study sites, laboratory analy-
ses such as complete blood counts, measurements of the
erythrocyte sedimentation rate, C-reactive protein and
serum creatinine, urinalysis with examination of urinary
sediment, and complement C3/C4 level tests, were routine-
ly performed. Anti-nuclear antibody titres, serum albumin,
anti-dsDNA antibody titres and spot (untimed) urine pro-
tein and creatinine were each measured by two of the three
sites.
Patient characteristics
The FAS consisted of 53 patients; 26 patients (49%) from
site 1, 16 (30%) from site 2 and 11 (21%) from site 3. Mean
age was 46.7 years and 43 patients (81%) were female. At
index, 23 patients (43%) had mild, 23 (43%) had moder-
ate, and 7 (13%) had severe SLE, based on the physician’s
clinical judgement (table 1). Physicians reported persistent
SLE activity in 31 patients (58%), a flare in 12 (23%), and
remission/low disease activity in 10 (19%).
All patients presented with at least one clinical manifes-
tation of SLE at index, with the majority (n = 44, 83%)
experiencing multiple manifestations. The most frequently
reported co-morbidities were hypertension and lupus
nephritis (also an SLE manifestation), each experienced
by 10 patients (19%). Haematological co-morbidities, liver
disease/problems and musculoskeletal co-morbidities were
documented for 8 (15%), 7 (13%) and 7 (13%) patients re-
spectively. Ten patients (19%) did not have any co-morbid
conditions (table 1).
Reasons for belimumab initiation included ineffective pre-
vious treatment, reported for 35 patients (66%), the intent
to reduce the corticosteroid dose (n = 25, 47%), and a
worsening condition (n = 15, 28%). Previous treatment not
tolerated, or inconvenient, and a patient request were re-
ported for 3 (6%), 1 (2%) and 1 (2%) patients respectively
(table 1).
All patients received the recommended dose of monthly
belimumab, 10 mg/kg IV, after the three induction infu-
sions on days 0, 14 and 28. None of the patients discon-
tinued belimumab during the six months post index. After
this period, 41 patients (77%) continued belimumab and 12
(23%) discontinued. The reasons for discontinuation were:
ineffective medication (n = 9, 75%), adverse drug reaction/
AE (prostate carcinoma) combined with lack of response
(n = 1, 8%), and patient request (n = 2, 17%).
Overall clinical response
At six months post index, the majority of patients (n = 44,
83%) showed an overall clinical improvement based on the
physician’s evaluations on a PGA-like scale. An improve-
ment of <20% was observed in 13 patients (25%), while
31 (58%) had an improvement of at least 20%, 12 (23%)
of at least 50% and 6 (11%) of at least 80%. Nine patients
(17%) had no improvement, and none experienced wors-
ening (fig. 1A).
Disease activity assessment: SELENA-SLEDAI
SELENA-SLEDAI scores at index and six months post in-
dex were available for a subgroup of 27 patients from two
study sites. In these patients, there was a decrease in mean
SELENA-SLEDAI score from 8.0 at index to 3.6 at six
months post index. The majority of these patients (n = 18,
67%) showed a reduction of ≥3.0 points, and 7 (26%) of
≥6.0 points (fig. 1B).
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Improvement from index in the most frequent clinical
and serological manifestations
At index, the five most frequent clinical and serological
manifestations were arthritis (n = 26, 49%), positive anti-
dsDNA antibody test (n = 25, 47%), fatigue (n = 19, 36%),
low complement (C3, C4, or haemolytic complement ac-
tivity [CH50]; n = 17, 32%), and rash (n = 16, 30%) (fig.
1C). Among patients presenting arthritis, fatigue and rash
at index, a ≥20% improvement was reported six months
post index for 17 (65%), 8 (42%) and 9 (56%) patients re-
spectively, with 10 (38%), 3 (16%) and 6 (38%) patients
experiencing a ≥50% improvement. At six months post in-
dex, 10 (40%) and 3 (18%) patients had a ≥20% improve-
ment in anti-dsDNA antibody levels and C3, C4, or CH50
levels respectively, and 4 (16%) and 2 (12%) patients had
a ≥50% improvement (fig. 1C).
Concomitant medications
Data on the overall use of corticosteroids were available
for 53 patients and data on the corticosteroid dose at index
and six months post index were available for 42 patients.
At index, 41 patients (77%, n = 53) received oral corti-
costeroids; mean dose was 11.6 mg/day (n = 42; fig. 2).
During the six months post index, patients experienced a
mean dose reduction of 5.7 mg/day to a mean dose of 5.9
mg/day (fig. 2). Overall, corticosteroid dose remained sta-
ble in nine patients (21%), increased in two (5%), and de-
creased in 28 (67%) patients during the six months post in-
dex. One patient (2%) initiated corticosteroids (mean dose
5 mg/day), and two (5%) discontinued. In contrast, during
the six months pre index, corticosteroid dose remained sta-
ble in 21 patients (50%), increased in 10 (24%) and de-
creased in 9 (21%), with only one patient (2%) achieving a
dose of <7.5 mg/kg.
Among the 31 patients who required a high dose (≥7.5 mg/
day) of corticosteroids at index, 65% had dose reductions
to low or no corticosteroids at six months post index (n =
18 to <7.5 mg/day and two discontinued use). The dose
of patients who were still receiving ≥7.5 mg/day corticos-
teroids at six months post index was also reduced. Over-
all, patients receiving a high dose of corticosteroids at in-
dex had a mean dose reduction of 7.8 mg/day at six months
post index.
Other concomitant SLE-related medications received at in-
dex included antimalarials (n = 44, 83%), azathioprine
Table 1: Patient characteristics (n = 53).
Patient characteristics At index (n = 53)
Female, n (%) 43 (81.1)
Age (years), mean (SD; range) 46.7 (13.6; 24–82)
BMI (kg/m2), mean (SD; range) 25.4 (5.1; 18.6–41.3)
Co-morbidities and manifestations of SLE (most
frequent), n (%)
None 10 (18.9)
Lupus nephritis 10 (18.9)
Hypertension 10 (18.9)
Other (ICD-10, Chapter III – haematologic) 8 (15.1)
Liver disease/problems 7 (13.2)
Other (ICD-10, Chapter XIII – musculoskeletal) 7 (13.2)
Time since SLE diagnosis, n (%) <1 year 1 (1.9)
1–5 years 23 (43.4)
6–10 years 18 (34.0)
>10 years 10 (18.9)
Unknown 1 (1.9)
SLE severity (physician assessed) at index, n
(%)
Mild 23 (43.4)
Moderate 23 (43.4)
Severe 7 (13.2)
Laboratory values at index (most frequent), n
(%)
High anti-dsDNA levels 30 (56.6)
Low C3 (<lower limit of normal) 27 (50.9)
Low C4 (<lower limit of normal) 20 (37.7)
Proteinuria (>upper limit of normal) 7 (13.2)
Leukopenia 6 (11.4)
Number of SLE clinical manifestationsa at index,
n (%)
1 9 (17.0)
2 14 (26.4)
3 8 (15.1)
4 15 (28.3)
≥5 7 (13.2)
Number of SLE medications (physician record-
ed) prior to index,
n (%)
1–3 36 (67.9)
4–5 13 (24.5)
>5 4 (7.5)
Reasons for initiation of belimumab therapy
(multiple reasons were permitted), n (%)
Previous treatment regimen not effective 35 (66.0)
Decrease use of corticosteroids 25 (47.2)
Patient condition worsening 15 (28.3)
Previous treatment not well tolerated 3 (5.7)
Previous treatment regimen inconvenient 1 (1.9)
Patient request 1 (1.9)
a Clinical manifestations include both clinical and serological symptoms, and were selected by the physicians based on their clinical judgement from a list of 30 pre-defined items
(appendix 1, table S2). BMI: body mass index; dsDNA: double-stranded deoxyribonucleic acid; SD: standard deviation; SLE: systemic lupus erythematosus
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(n = 22, 42%), cyclosporine (n = 1, 2%), methotrexate
(n = 9, 17%), mycophenolate mofetil (n = 7, 13%) and
NSAIDs (n = 1, 2%) (appendix 1, table S1). The use of
these medications remained stable throughout the study. At
six months pre index, the most common non-SLE thera-
pies were osteoporosis and antihypertensive medications
and dietary supplements, received by 38 (72%), 22 (42%)
and 11 (21%) patients respectively. The medication pattern
did not change during belimumab therapy, except for di-
Figure 1: Clinical outcomes. (A) Physicians’ evaluation of overall
clinical response at six months post index ( n = 53). (B) Change in
SELENA-SLEDAI score (n = 27). (C) Physician-assessed improve-
ment from index in clinical manifestations and biomarkers at six
months post index ( n = 53). a Calculated based on the number of
patients presenting the manifestation at index dsDNA, double-
stranded deoxyribonucleic acid. SELENA-SLEDAI: Safety of Estro-
gens in Lupus Erythematosus National Assessment-SLE Disease
Activity Index; SD: standard deviation
Figure 2: Change in oral corticosteroid use among patients who
received corticosteroids by initial dosage group (n = 42). SD, stan-
dard deviation
etary supplements, for which intake decreased to 5 (9%)
patients at six months post index.
Safety
Two serious AEs were reported during the study period.
Mammary carcinoma was considered by the investigator to
be possibly related to belimumab treatment, and prostate
carcinoma was considered unrelated to belimumab treat-
ment. No deaths were reported.
Discussion
This observational study investigated the role of belimum-
ab in the management of patients with SLE in clinical prac-
tice in Switzerland. Belimumab in addition to SoC is ap-
proved to reduce disease activity of adult patients with
active, autoantibody-positive SLE, and is reimbursed in
patients with a high disease activity (e.g. positive anti-
dsDNA and low complement levels) [9, 24] despite SoC
therapy. The data show that over a six-month treatment
period, patients had an overall improvement in disease ac-
tivity, with a decrease in SELENA-SLEDAI score, im-
provements in the most frequent clinical and serological
manifestations of SLE and, importantly, a dose reduction
of concomitant corticosteroid medication.
A key finding of this study was the reduction in corti-
costeroid use observed, with 65% of patients in the high-
dose group having their dose reduced to below 7.5 mg/day
and two patients discontinuing steroids. Reducing the use
of corticosteroids is important in the treatment of SLE, as
prolonged use of high-dose corticosteroids, predominantly
prescribed to patients with high disease activity, is associ-
ated with significant toxicity and organ damage, and many
patients with more severe SLE are children and adoles-
cents [4, 25–27]. This steroid-sparing effect of belimumab
was observed in post hoc analyses of the belimumab clini-
cal trials and the long-term extension study [28, 29].
The effectiveness of belimumab demonstrated in this study
supports similar findings in the other OBSErve studies,
in which the average SELENA-SLEDAI score also de-
creased markedly, with parallel reductions in corticosteroid
use [13–17]. Interestingly, the real-world observations in
the United States, Canada, Germany and Spain saw greater
clinical improvements and steroid sparing effects. For ex-
ample, in the United States, Germany and Canada, an im-
provement of more than 50% was observed in 48.7%, 42%
and 57.7% of patients, compared with in 23% of patients
in Switzerland [14–17]. The greater clinical improvements
and steroid sparing effects observed in these studies may
have been due to a higher disease severity at index, based
on physician’s clinical judgement, and a higher baseline
SELENA-SLEDAI score, compared with this study, result-
ing in a more pronounced response to belimumab treat-
ment, which was also observed in post hoc analyses of the
belimumab Phase III trials [28].
Belimumab was well tolerated; no patients discontinued
belimumab during the six months of therapy, which is in
line with belimumab treatment recommendations (treat-
ment for a minimum of six months before belimumab dis-
continuation is considered) [9].
There is no standard SLE assessment tool recommended
by organisations of rheumatology professionals such as the
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European League against Rheumatism or the American
College of Rheumatology. In this study, we found that the
use of SELENA-SLEDAI varied between sites and was
used for approximately half of all patients, with the ma-
jority of physicians not using any disease assessment tools
in their routine SLE management. The lack of a consistent
use of measures of disease activity demonstrates a gap in
the real-world care of patients with SLE in Switzerland.
This gap was also highlighted by the OBSErve studies con-
ducted in the United States and Canada [14, 17]. A stan-
dard assessment practice would prove helpful in monitor-
ing the disease course and the effect of changes in therapy
for a single patient, as already highlighted by Strand et
al. nearly two decades ago [30]. Furthermore, it would al-
so enable comparisons to be made between clinical sites
throughout Switzerland. To this day, no general recom-
mendations for the optimal measurement of clinical out-
comes in SLE have been developed by, for example, the
OMERACT (Outcome Measures in Rheumatology) group
(www.omeract.org). In 2014, van Vollenhoven et al. fur-
ther emphasised that clear definitions for assessing disease
activity should be developed [31]. Furthermore, disease
scores such as SELENA-SLEDAI are difficult to use for
retrospective chart review analyses, as physicians often fail
to document patient outcomes that they do not regard as
clinically important.
The study has some limitations. Firstly, the analyses were
conducted with relatively low patient numbers, particularly
for the SELENA-SLEDAI assessments, which were per-
formed only in approximately 50% of patients. Although
there may be variation in the SLE care experience between
different sites, the three hospitals which participated in
this study represent 50% of all clinical sites specialising
in treating patients with SLE in Switzerland. These sites
were selected from the German-speaking part of Switzer-
land only. A second limitation is that the primary endpoint
was based on the physician’s individual clinical judge-
ment. Furthermore, the information provided in the CRFs
was an interpretation of the patients’ medical charts, and
under-reporting may have occurred if not all events were
recorded. Thirdly, the study did not include a control group
to compare belimumab treatment with other SoC therapies.
The fourth possible bias of this study is the relatively
short follow-up of six months. However, because the effi-
cacy measure (SLE responder index) in the BLISS-52 and
BLISS-76 studies [10, 11] was found to plateau after six
months, and the primary endpoint of the present study was
the efficacy/effectiveness of belimumab, we considered the
chosen length of follow-up to be adequate. This is further
supported by the Swiss and the European product informa-
tion, which recommend considering discontinuation of be-
limumab if no improvement is observed after six months
[9, 24]. The length of follow-up may be different for stud-
ies assessing belimumab safety and the incidence of ad-
verse events.
The incomplete documentation for changes in and/or oc-
currence of anti-nuclear antibody and anti-dsDNA anti-
body titres could be considered a further limitation.
Considering the limitations mentioned above, we think that
observational studies performed in different national co-
horts, such as the OBSErve study in Switzerland, may
greatly improve our understanding of how new therapies
are used in an everyday clinical practice, and how effective
they are in a national setting. Such observational data on
national treatment patterns may be the only source of such
information, but they are a very important source, because
large, multinational Phase III/IV clinical trials often do not
analyse specific differences between participating coun-
tries. The findings described here may prove useful in de-
signing future treatment strategies for patients with SLE in
Switzerland.
In conclusion, this is the first observational study of treat-
ment patterns in patients with SLE and the clinical effec-
tiveness of belimumab for patients with SLE receiving be-
limumab as part of their usual care in Switzerland. The
data provide further evidence to support the previously
demonstrated steroid-sparing effect of belimumab, which
has important clinical implications, particularly for young
patients with high disease activity. Variability in the use of
disease assessment tools highlights a care gap in the treat-
ment of SLE in the real-world setting.
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Appendix 1
Supplementary tables
Table S1: Number of patients receiving concomitant SLE medications other than corticosteroids (n = 53).
6 months
pre index
At index 6 months post index
Antimalarials (e.g. hydroxychloroquine/chloroquine), n (%) 44 (83) 44 (83) 44 (83)
Azathioprine, n (%) 24 (45) 22 (42) 22 (42)
Cyclosporine, n (%) 1 (2) 1 (2) 0 (0)
Methotrexate, n (%) 10 (19) 9 (17) 8 (15)
Mycophenolate mofetil, n (%) 9 (17) 7 (13) 7 (13)
NSAIDs, n (%) 2 (4) 1 (2) 1 (2)
Rituximab/MabThera, n (%) 2 (4) 0 (0) 0 (0)
NSAIDs: non-steroidal anti-inflammatory drugs; SLE: systemic lupus erythematosus
Table S2: Pre-defined clinical manifestations of SLE listed in the Patient Case Report Form.
Musculoskeletal Arthritis
Myositis
Central nervous system Cerebrovascular accident
Organic brain syndrome
Cranial nerve neuropathy
Seizure
Psychosis
Headache
Cardiopulmonary Pericarditis
Pleurisy
Myocarditis
Mucocutaneous Rash
Mucosal ulcers
Alopecia
Immunologic Increased DNA bindinga
Low complement (C3, C4, or CH50)b
Renal Proteinuriac
Pyuriad
Constitutional Inability to taper steroids
Fatigue
Fever
Weight loss
Haematologic Thrombocytopeniae
Leucopeniaf
Haemolytic anaemia
Circulatory Vasculitis
Visual/ocular
Gastrointestinal
Renal/genitourinary Urinary casts
Haematuria
a>25% binding by Farr assay, or above-normal range for testing laboratory; bDecrease in C3, C4, or CH50 below the lower limit of normal for testing laboratory; c>0.5 g/24h; d>5
white blood cells/high power field; e<100,000 platelets/mm3; f<3000 white blood cells/mm3. C3, Complement 3; C4, Complement 4; CH50, haemolytic complement activity; DNA,
deoxyribonucleic acid; SLE, systemic lupus erythematosus
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